Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artículo Open Access |
| Veröffentlicht: |
Wiley
2024
|
| Schlagworte: | |
| Online-Zugang: | https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/cmdc.202400549 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Inhaltsangabe:
- Lactam Truncation Yields a Dihydroquinazolinone Scaffold with Potent Antimalarial Activity that Targets PfATP4 Trent D. Ashton Petar P. S. Calic Madeline G. Dans Zi Kang Ooi Qingmiao Zhou Katie Loi Kate E. Jarman Josephine Palandri Deyun Qiu Adele M. Lehane Bikash Maity Nirupam De Mufuliat T. Famodimu Michael J. Delves Emma Y. Mao Maria R. Gancheva Danny W. Wilson Mrittika Chowdury Tania F. de Koning‐Ward Delphine Baud Stephen Brand Paul F. Jackson Alan F. Cowman Brad E. Sleebs ChemMedChem AbstractThe emergence of resistance against current antimalarial treatments has necessitated the need for the development of novel antimalarial chemotypes. Toward this goal, we recently optimised the antimalarial activity of the dihydroquinazolinone scaffold and showed it targeted PfATP4. Here, we deconstruct the lactam moiety of the tricyclic dihydroquinazolinone scaffold and investigate the structure‐activity relationship of the truncated scaffold. It was shown that SAR between scaffolds was largely transferrable and generated analogues with potent asexual stage activity. Evaluation of the truncated analogues against PfATP4 mutant drug‐resistant parasite strains and in assays measuring PfATP4‐associated ATPase activity demonstrated retention of PfATP4 as the molecular target. Analogues exhibited activity against both male and female gametes and multidrug resistant parasites. Limited efficacy of analogues in a P. berghei asexual stage mouse model was attributed to their moderate metabolic stability and low aqueous stability. Further development is required to address these attributes toward the potential use of the dihydroquinazolinone class in a curative and transmission blocking combination antimalarial therapy. 10.1002/cmdc.202400549 http://creativecommons.org/licenses/by/4.0/